These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38517480)

  • 1. Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC.
    Swiecicki PL; Bellile E; Dragovic AF; McHugh J; Udager A; Mierzwa ML; Shah J; Heft-Neal M; Rosko A; Malloy KM; Casper K; Chinn SB; Shuman AG; Stucken C; Chepeha DB; Wolf GT; Bradford CR; Eisbruch A; Prince ME; Worden FP; Spector ME
    Clin Cancer Res; 2024 Jun; 30(11):2393-2401. PubMed ID: 38517480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS).
    Cannon RB; Houlton JJ; Patel S; Raju S; Noble A; Futran ND; Parvathaneni U; Méndez E
    Oral Oncol; 2018 Nov; 86():296-300. PubMed ID: 30409315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.
    Cramer JD; Ferris RL; Kim S; Duvvuri U
    Oral Oncol; 2018 Dec; 87():170-176. PubMed ID: 30527235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: An institutional experience.
    Wotman M; Ghaly M; Massaro L; Tham T; Seetharamu N; Kamdar D; Frank D; Kraus D; Teckie S
    Am J Otolaryngol; 2019; 40(5):684-690. PubMed ID: 31229365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
    J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Meldgaard Justesen M; Kronberg Jakobsen K; Fenger Carlander AL; Hjordt Holm Larsen M; Wessel I; Kiss K; Friborg J; Ibrahim Channir H; Rubek N; Grønhøj C; von Buchwald C
    Oral Oncol; 2024 May; 152():106783. PubMed ID: 38569317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of surgically treated human papillomavirus-related oropharyngeal squamous cell carcinoma with N3 disease.
    Zenga J; Haughey BH; Jackson RS; Adkins DR; Aranake-Chrisinger J; Bhatt N; Gay HA; Kallogjeri D; Martin EJ; Moore EJ; Paniello RC; Rich JT; Thorstad WL; Nussenbaum B
    Laryngoscope; 2017 Sep; 127(9):2033-2037. PubMed ID: 28008626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
    J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
    Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.
    Cracchiolo JR; Baxi SS; Morris LG; Ganly I; Patel SG; Cohen MA; Roman BR
    Cancer; 2016 May; 122(10):1523-32. PubMed ID: 26970050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes for potentially Resectable patients undergoing primary chemoradiation treatment for T1-T2 HPV Negative oropharyngeal squamous cell carcinoma.
    Laxague F; Fnais N; Son HY; Alzahrani F; Mymryk JS; Barrett JW; Tay KY; Leung A; Theurer J; Nichols AC; Palma DA
    Head Neck; 2024 Nov; 46(11):2789-2797. PubMed ID: 38779999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT Poorly Predicts AJCC 8th Edition Pathologic Staging in HPV-Related Oropharyngeal Cancer.
    Snyder V; Goyal LK; Bowers EMR; Kubik M; Kim S; Ferris RL; Johnson JT; Duvvuri U; Gooding WE; Branstetter BF; Rath TJ; Sridharan SS
    Laryngoscope; 2021 Jul; 131(7):1535-1541. PubMed ID: 33428218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
    Yoshida EJ; Luu M; Mallen-St Clair J; Mita AC; Scher KS; Lu DJ; Nguyen AT; Shiao SL; Ho AS; Zumsteg ZS
    Cancer; 2020 Jan; 126(1):58-66. PubMed ID: 31536144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.
    Hasegawa M; Maeda H; Deng Z; Kiyuna A; Ganaha A; Yamashita Y; Matayoshi S; Agena S; Toita T; Uehara T; Suzuki M
    Int J Oncol; 2014 Sep; 45(3):1017-26. PubMed ID: 24969413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
    Hu Q; Li F; Yang K
    PeerJ; 2024; 12():e17391. PubMed ID: 38784388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Assessment of a Novel Composite Pathologic Risk Stratification for Surgically Resected Human Papillomavirus-Associated Oropharyngeal Cancer.
    Cramer JD; Dundar Y; Hotaling J; Raza SN; Lin HS
    JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1105-1114. PubMed ID: 31042786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
    Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.